Selling by month
Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.
Disclosed planOne dollar scale for every month; the tallest bar is labeled
Pattern
What the filings show, past 12 months. Nothing here rates or predicts.
- Sold in 2 of the 13 calendar months from Oct 2025 to Oct 2026: Nov 2025 and May 2026.
- Largest single sale: $775K (1,497 shares) of Madrigal Pharmaceuticals, Inc. on May 22, 2026. Filing
- Last sale before this period: Nov 7, 2024.
Roles from filings
Every company we track where this person has filed, newest filing first.
| Company | Title | First filing | Latest filing |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, plc (KNSA) | Director | Mar 6, 2019 | Aug 4, 2026 |
| Kodiak Sciences Inc. (KOD) | Director | Oct 3, 2018 | Jul 2, 2026 |
| Madrigal Pharmaceuticals, Inc. (MDGL) | Director | Nov 21, 2016 | Jun 18, 2026 |
| Incyte (INCY) | Former EVP, Chief Drug Dev Officer | Jan 29, 2009 | Jan 8, 2016 |
Also a director at
Kodiak Sciences Inc. (KOD), Madrigal Pharmaceuticals, Inc. (MDGL)
Recent filings
The last 5 days with transactions, newest first, one line per trade date. Each number links to an SEC filing.
- Aug 1, 2026, Kiniksa Pharmaceuticals International, plc: 403 shares vested. 1 filing: 1
- Jun 17, 2026, Madrigal Pharmaceuticals, Inc.: 454 shares granted. 1 filing: 1
- May 29, 2026, Kiniksa Pharmaceuticals International, plc: 2,799 shares vested. 1 filing: 1
- May 22, 2026, Madrigal Pharmaceuticals, Inc.: sold 5,682 shares for $2.9M, under a disclosed plan. 1 filing: 1
- Feb 23, 2026, Madrigal Pharmaceuticals, Inc.: 2,500 shares acquired by exercising options. 1 filing: 1
This page shows only what this person reported on SEC ownership filings. See the methodology. Spotted something wrong? Report an error.